Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Journalists killed by Israeli strike in southern Lebanon - 2The most effective method to Go with Informed Choices on Vehicle Leases
- 3Clocks to go forward one hour in Europe as summer time starts
- 4the 6 Shrewd Beds for seniors: A Complete Survey
- 5Excited visitors for NASA's moon launch jockey for prime views
- Linda Hamilton, 69, says she doesn't want to 'chase longevity'
- The Excursion to Monetary Proficiency: Individual budget Triumphs
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Fears of global aluminum shortages intensify
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- Claim that Israel opened 'sewage dam' into Gaza's main river undersells sanitation crisis
- NASA's make-or-break moon shot
- Track down Your Optimal Conservative Vehicle: Famous Brands to Consider
- Figure out How to Take part in Open Conversations Around 5G Pinnacles
